IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 37 filers reported holding IMPEL NEUROPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,126 | -81.3% | 225,874 | -44.7% | 0.10% | -85.7% |
| Q2 2023 | $518,578 | -9.3% | 408,329 | 0.0% | 0.67% | -38.9% |
| Q1 2023 | $571,661 | -62.7% | 408,329 | 0.0% | 1.10% | -53.8% |
| Q4 2022 | $1,531,234 | -23.0% | 408,329 | 0.0% | 2.38% | -37.8% |
| Q3 2022 | $1,989,000 | -47.7% | 408,329 | 0.0% | 3.82% | -34.0% |
| Q2 2022 | $3,806,000 | +81.1% | 408,329 | +23.7% | 5.79% | +454.3% |
| Q1 2022 | $2,102,000 | -26.2% | 330,000 | 0.0% | 1.04% | -25.7% |
| Q4 2021 | $2,848,000 | -29.1% | 330,000 | 0.0% | 1.41% | -43.4% |
| Q3 2021 | $4,019,000 | +37.6% | 330,000 | 0.0% | 2.48% | +84.3% |
| Q2 2021 | $2,921,000 | – | 330,000 | – | 1.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NVP Associates, LLC | 3,077,198 | $11,539,493 | 11.26% |
| Vivo Capital, LLC | 2,884,789 | $43,272 | 4.98% |
| venBio Partners LLC | 2,759,791 | $10,349,216 | 3.21% |
| 5AM Venture Management, LLC | 2,884,791 | $10,817,966 | 2.91% |
| LASRY MARC | 408,329 | $1,531,234 | 2.38% |
| DCF Advisers, LLC | 325,825 | $1,221,844 | 0.83% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $15,509,891 | 0.52% |
| EPIQ PARTNERS, LLC | 18,646 | $69,923 | 0.05% |
| J. Goldman & Co LP | 200,219 | $750,821 | 0.04% |
| MCDONALD PARTNERS LLC | 11,700 | $43,875 | 0.02% |